Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company based in Nerviano, Italy, has announced a licensing agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company located in Milan, to collaborate on the development and commercialization of a novel peptide-drug conjugate (PDC). The agreement will allow ITF to utilise NMS’s proprietary linker-payload technology to develop a new PDC product candidate, with ITF taking responsibility for the generation of the target peptide and all associated activities related to the product candidates.
Dr Christian Steinkühler, Chief Scientific Officer of Italfarmaco Group, expressed enthusiasm for the partnership, highlighting the potential of NMS’s technology to address unmet medical needs in oncology. Similarly, Dr Hugues Dolgos, Chief Executive Officer of NMS and NMS Group, emphasized the significance of the collaboration in broadening the applicability of their technology.
NMS is recognised for its focus on the discovery and development of innovative cancer therapies, with a particular emphasis on kinase and linker-payload platforms. Through this collaboration, ITF will be able to leverage NMS’s specialized technology to develop peptide-drug conjugates for the treatment of oncology indications.
The licensed linker payload includes optimised features and has demonstrated potent antiproliferative activity across a wide range of tumour cell lines. Additionally, it has shown greater potency than existing treatments in chemotherapy-resistant cell lines, making it a promising option for addressing the challenges of heterogeneous and chemotherapy-resistant solid tumours.
The collaboration between Nerviano Medical Sciences and Italfarmaco Group represents a significant step in advancing the development of innovative cancer therapeutics. By combining NMS’s proprietary technology with ITF’s expertise in peptide-based oncology therapeutics, the companies aim to develop a pipeline of novel peptide-drug conjugates that have the potential to address the needs of patients with a variety of cancer types.
Italfarmaco Group is well-established as a specialty pharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of prescription and non-prescription products globally. With a focus on specialty and rare diseases, the company’s research and development efforts have produced promising results, particularly in the development of HDAC inhibitors for new therapeutic treatments.
Nerviano Medical Sciences S.r.l. is committed to the discovery and clinical development of small molecule NCEs for oncology, with an extensive pipeline of innovative medicines targeting a variety of cancer types. The company’s proprietary kinase and linker-payload platforms have been instrumental in the development of approved targeted drugs, as well as a range of preclinical to clinical stage products.
As the collaboration between NMS and ITF progresses, the companies remain dedicated to advancing the development of novel oncological therapies. The partnership highlights the value of combining expertise from multiple organisations to drive innovation and address the complex challenges presented by cancer.
In conclusion, the agreement between Nerviano Medical Sciences and Italfarmaco Group represents a significant milestone in the field of oncology therapeutics, with the potential to generate a pipeline of innovative cancer treatments that could benefit patients worldwide. By harnessing the unique capabilities of both companies, the collaboration aims to deliver new solutions for addressing the diverse and complex needs of cancer patients.
For media inquiries:
For Italfarmaco:
Trophic Communications
Contact: Charlotte Spitz or Jacob Verghese
Phone: +49 (0)151 7441 6179
Email: [email protected]
For Nerviano Medical Sciences:
Contact: Sidney Dung
Email: [email protected]
+ There are no comments
Add yours